<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690560</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000589530</org_study_id>
    <secondary_id>CALACASS-3RCHOPZ</secondary_id>
    <secondary_id>INCA-RECF0624</secondary_id>
    <secondary_id>EUDRACT-2006-006179-19</secondary_id>
    <secondary_id>CALACASS-2006/27</secondary_id>
    <nct_id>NCT00690560</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma</brief_title>
  <official_title>International Phase II Study Evaluating the Association of CHOP-rituximab With Consolidation by Early Ibritumomab Tiuxetan-Y90 in Patients Aged 65 to 80 Years With CD20+ Large Cell Malignant Lymphoma and no Prior Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin, vincristine, and&#xD;
      cyclophosphamide, work in different ways to stop the growth of cancer cells, either by&#xD;
      killing the cells or by stopping them from dividing. Steroid therapy, such as prednisone, may&#xD;
      be effective in treating cancer and blocking the body's immune response. Monoclonal&#xD;
      antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can block cancer growth&#xD;
      in different ways. Some block the ability of cancer cells to grow and spread. Others find&#xD;
      cancer cells and help kill them or carry cancer-killing substances to them. Giving&#xD;
      chemotherapy together with prednisone and monoclonal antibody therapy may kill more cancer&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving doxorubicin together with&#xD;
      vincristine, cyclophosphamide, prednisone, and rituximab followed by rituximab and yttrium Y&#xD;
      90 ibritumomab tiuxetan works in treating patients with newly diagnosed large B-cell&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine event-free survival of patients with large B-cell lymphoma treated with CHOP-R&#xD;
           followed by consolidation therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine overall survival.&#xD;
&#xD;
        -  Evaluate relapse-free survival for patients achieving complete or partial response.&#xD;
&#xD;
        -  Determine the rate of disease progression.&#xD;
&#xD;
        -  Determine response rate at the end of study therapy.&#xD;
&#xD;
        -  Assess the toxicities of this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Induction therapy: Patients receive the CHOP-R regimen comprising doxorubicin&#xD;
           hydrochloride IV, vincristine IV, cyclophosphamide IV, and rituximab IV on day 1 and&#xD;
           prednisone IV on days 1-5. Treatment repeats every 2 weeks for 2 courses.&#xD;
&#xD;
      Patients who achieve complete or partial response, as assessed by PET/CT scan, receive a&#xD;
      third course of induction therapy.&#xD;
&#xD;
        -  Consolidation therapy: Patients receive rituximab IV on days -8 to 0 and yttrium Y 90&#xD;
           ibritumomab tiuxetan IV on day 0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival in responding patients</measure>
    <time_frame>up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of disease progression</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>up to six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-CHOP14 chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>R-CHOP14 chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>R-CHOP14 chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>R-CHOP14 chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>R-CHOP14 chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>R-CHOP14 chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
    <arm_group_label>R-CHOP14 chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed large B-cell lymphoma&#xD;
&#xD;
               -  Stage I, II, III, or IV disease&#xD;
&#xD;
               -  Bone marrow or lymph node involvement by small cell lymphoma allowed&#xD;
&#xD;
               -  No serious, progressive pathology (at investigator's discretion)&#xD;
&#xD;
          -  CD20-positive disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No prior indolent lymphoma, treated or not&#xD;
&#xD;
          -  No meningeal or CNS lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  International prognostic index &lt; 2 (adjusted for age)&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin ≤ 30 mmol/L&#xD;
&#xD;
          -  Creatinine ≤ 150 μmol/L&#xD;
&#xD;
          -  HIV, hepatitis B virus, and hepatitis C virus negative (unless after vaccine)&#xD;
&#xD;
          -  No contraindication to chemotherapy or immunotherapy&#xD;
&#xD;
          -  No cancer in the past 5 years except basal cell skin cancer or carcinoma in situ of&#xD;
             the cervix&#xD;
&#xD;
          -  No contraindication to a venous catheter&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 30 days since prior and no other concurrent investigational treatment&#xD;
&#xD;
          -  No prior therapy&#xD;
&#xD;
          -  No concurrent participation in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederec Peyrade, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>February 8, 2015</last_update_submitted>
  <last_update_submitted_qc>February 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

